Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Breast cancers with low HER2 expression can be difficult to identify using immunohistochemistry or in situ hybridization. Approximately one in three HER2-ultralow breast cancers will be initially ...

3 HER2 IHC testing, which helps identify patients with advanced HER2-positive solid tumors who may be eligible for a targeted treatment. 4 FOLR1 IHC testing, which helps identify patients with ...